<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>66(12)</volume><submitter>Karouta C</submitter><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Dopaminergic dysregulation plays a critical role in myopia development in animal models. Although its relevance to human myopia remains uncertain, the observation that methylphenidate hydrochloride (MPH)-a dopamine (DA) and norepinephrine (NE) uptake inhibitor-slows myopia progression in children suggests a possible link. This study aimed to investigate whether MPH can inhibit myopic growth and elucidate the underlying mechanisms using an animal model.&lt;h4>Methods&lt;/h4>MPH was administered via oral, topical, or intravitreal routes for 7 days (minimum 5 per group) to chicks undergoing form-deprivation myopia (FDM). Myopia was assessed by refraction and axial length. Retinal DA and NE dynamics-including synthesis, release, uptake, breakdown (DA only), extracellular levels, and </pubmed_abstract><journal>Investigative ophthalmology &amp; visual science</journal><pagination>52</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12468103</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Methylphenidate Inhibits the Development of Myopia by Altering Dopamine and Norepinephrine Reuptake.</pubmed_title><pmcid>PMC12468103</pmcid><pubmed_authors>Thomson K</pubmed_authors><pubmed_authors>Morgan I</pubmed_authors><pubmed_authors>Booth L</pubmed_authors><pubmed_authors>Ashby R</pubmed_authors><pubmed_authors>Karouta C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Methylphenidate Inhibits the Development of Myopia by Altering Dopamine and Norepinephrine Reuptake.</name><description>&lt;h4>Purpose&lt;/h4>Dopaminergic dysregulation plays a critical role in myopia development in animal models. Although its relevance to human myopia remains uncertain, the observation that methylphenidate hydrochloride (MPH)-a dopamine (DA) and norepinephrine (NE) uptake inhibitor-slows myopia progression in children suggests a possible link. This study aimed to investigate whether MPH can inhibit myopic growth and elucidate the underlying mechanisms using an animal model.&lt;h4>Methods&lt;/h4>MPH was administered via oral, topical, or intravitreal routes for 7 days (minimum 5 per group) to chicks undergoing form-deprivation myopia (FDM). Myopia was assessed by refraction and axial length. Retinal DA and NE dynamics-including synthesis, release, uptake, breakdown (DA only), extracellular levels, and </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-06-03T21:13:09.168Z</modification><creation>2026-05-01T03:10:39.497Z</creation></dates><accession>S-EPMC12468103</accession><cross_references><pubmed>40985800</pubmed><doi>10.1167/iovs.66.12.52</doi></cross_references></HashMap>